Adriamycin cytotoxicity may stimulate growth of hepatocellular tumours in an experimental model for adjuvant systemic chemotherapy in liver transplantation

• Adjuvant treatment with adriamycin has been suggested to improve results after liver transplantation for hepatocellular cancer. Here we have applied an animal model for evaluation of treatment with adriamycin and/or cyclosporine A on liver tumour growth. Three chemically induced rat liver tumours with various degree of differentiation were transferred to the spleens of syngenic rats. Each recipient group was divided into four subgroups, treated with adriamycin and/or cyclosporine A or none of the drugs. When the tumour was well differentiated no proliferation was found in any of the subgroups. When the tumour exhibited a more pronounced dysplasia, adriamycin stimulated tumour growth. This effect was further increased by cyclosporine. In the animals transplanted with the most aggressive tumour, adriamycin inhibited tumour growth. When given together with cyclosporine this inhibition was counteracted. These data suggest that adriamycin, especially when given together with cyclosporine, may have a stimulatory effect on liver tumour cell growth.

Nyckelord

Adjuvant therapy

Adriamycin

Antioxidants

Cyclosporine A

Hepatocellular carcinoma

Liver transplantation

cyclosporin A

doxorubicin

antioxidant

glutathione reductase

animal experiment

animal model

animal tissue

article

cell differentiation

cell proliferation

controlled study

cytotoxicity

dysplasia

liver cell carcinoma

male

nonhuman

priority journal

rat

spleen

tumor growth

adjuvant chemotherapy

animal

drug effect

liver tumor

metabolism

multimodality cancer therapy

pathology

Wistar Kyoto rat

Animals

Chemotherapy

Adjuvant

Combined Modality Therapy

Liver Neoplasms

Experimental

Rats

Rats

Inbred WKY

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)